Skip to main content
. 2022 May 19;23:420. doi: 10.1186/s13063-022-06353-2

Table 2.

Primary, secondary and tertiary outcomes of the study

Outcome Description
Primary outcomes Grade 2 or higher HFS (proportion)
Secondary

All grades of HFS (proportion)

Time to develop HFS (days)

Patient-reported outcomes using HFS 14 questionnaire

Adherence with topical application

HFS related dose changes and delays in capecitabine

Adverse events (NCI CTCAE version 5.0)

Tertiary COX-2 levels

HFS hand-foot syndrome, NCI National Cancer Institute, CTCAE Common Terminology Criteria for Adverse Events, COX-2 cycloxygenase-2